You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

BRAFV600E/K

Showing 1 - 25 of 3,356
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in Boston, Harrison, New York (Dabrafenib, Trametinib, Phenformin)

Active, not recruiting
  • Melanoma
  • Boston, Massachusetts
  • +2 more
Jun 14, 2022

BRAF Mutant Metastatic Melanoma Trial in San Francisco (BKM120 Combined with Vemurafenib (PLX4032))

Completed
Has Results
  • BRAF Mutant Metastatic Melanoma
  • BKM120 Combined with Vemurafenib (PLX4032)
  • San Francisco, California
    University of California, San Francisco
Aug 6, 2020

Melanoma Trial in New York (Dabrafenib)

Completed
Has Results
  • Melanoma
  • New York, New York
    Memorial Sloan Kettering Cancer Center
May 8, 2020

Unresectable or Metastatic BRAFV600E Mutant Melanoma Patients

Recruiting
  • Melanoma (Skin)
  • +2 more
    • Evora, Portugal
      Hospital Evora
    May 30, 2022

    Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas Trial in Canada, United States (Vemurafenib)

    Active, not recruiting
    • Pediatric Recurrent/Refractory BRAFV600E-mutant Gliomas
    • Los Angeles, California
    • +20 more
    Jan 4, 2023

    Metastatic Colorectal Cancer, BRAF V600E Mutation Positive Trial in France (Collection of blood samples)

    Not yet recruiting
    • Metastatic Colorectal Cancer
    • BRAF V600E Mutation Positive
    • Collection of blood samples
    • Avignon, France
    • +26 more
    Nov 25, 2022

    Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation Trial in Villejuif (Trametinib,

    Active, not recruiting
    • Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
    • Villejuif, Val De Marne, France
      Gustave Roussy
    Sep 27, 2021

    First Line Treatment for BRAFV600E Mutant Metastatic Colorectal

    Completed
    • BRAF V600E Mutation Positive
    • Metastatic Colorectal Cancer
    • Non Interventional study
    • St. Veit/Glan, Austria
    • +33 more
    Jan 20, 2023

    Clinical Stage IV Cutaneous Melanoma AJCC v8, Locally Advanced Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 Trial

    Active, not recruiting
    • Clinical Stage IV Cutaneous Melanoma AJCC v8
    • +4 more
    • Dabrafenib Mesylate
    • +3 more
    • Philadelphia, Pennsylvania
      Perelman Center for Advanced Medicine
    Dec 29, 2021

    Melanoma Trial in Beijing (HL-085, Vemurafenib)

    Recruiting
    • Melanoma
    • Beijing, Beijing, China
      Beijing Cancer Hospital
    Apr 10, 2022

    Metastatic Colorectal Cancer Trial in Boston (Dabrafenib, Trametinib, PDR001)

    Recruiting
    • Metastatic Colorectal Cancer
    • Boston, Massachusetts
    • +1 more
    Jun 24, 2022

    Differentiated Thyroid Cancer Trial in Worldwide (Dabrafenib, Trametinib, Trametinib )

    Recruiting
    • Differentiated Thyroid Cancer
    • Caba, Buenos Aires, Argentina
    • +41 more
    Nov 25, 2022

    Melanoma Trial in Italy (dabrafenib, Trametinib)

    Recruiting
    • Melanoma
    • Meldola, Forlì-Cesena, Italy
    • +15 more
    Mar 18, 2022

    Percentage of BRAFV600E Alleles and Outcome in Thyroid Carcinoma

    Not yet recruiting
    • Papillary Thyroid Cancer
      • Baronissi, Salerno, Italy
        Department of Medicine and Surgery, Univeristy of Salerno
      Dec 10, 2020

      BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present, Thyroid Gland Anaplastic Carcinoma Trial in Duarte, Columbus (Dabrafenib,

      Recruiting
      • BRAF NP_004324.2:p.V600E
      • +2 more
      • Duarte, California
      • +1 more
      Jan 19, 2023

      Melanoma Metastatic, BRAF V600 Mutation Trial in Italy (Experimental combination beyond Focal Progression, Pembrolizumab or

      Active, not recruiting
      • Melanoma Metastatic
      • BRAF V600 Mutation
      • Experimental combination beyond Focal Progression
      • Pembrolizumab or Nivolumab
      • Bari, BA, Italy
      • +13 more
      Dec 1, 2021

      Pathologic Stage IIIB Cutaneous Melanoma AJCC v8, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8, Pathologic Stage IIID

      Active, not recruiting
      • Pathologic Stage IIIB Cutaneous Melanoma AJCC v8
      • +2 more
      • Houston, Texas
        M D Anderson Cancer Center
      Aug 9, 2022

      BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Melanoma Trial in Boston (drug, biological, other)

      Terminated
      • BRAF V600E Mutation Present
      • +7 more
      • Boston, Massachusetts
      • +1 more
      Mar 9, 2022

      Melanoma Trial in Worldwide (Atezolizumab, Atezolizumab Placebo, Cobimetinib)

      Active, not recruiting
      Has Results
      • Melanoma
      • Birmingham, Alabama
      • +115 more
      Jul 11, 2022

      BRAF or NRAS Mutant Metastatic Melanoma Trial in Worldwide (MEK162)

      Active, not recruiting
      Has Results
      • BRAF or NRAS Mutant Metastatic Melanoma
      • Fayetteville, Arkansas
      • +20 more
      Nov 18, 2021

      Metastatic Melanoma Trial in Darlinghurst, Sydney, Brisbane (Palliative radiotherapy, Dabrafenib and trametinib (combination))

      Completed
      • Metastatic Melanoma
      • Palliative radiotherapy
      • Dabrafenib and trametinib (combination)
      • Darlinghurst, New South Wales, Australia
      • +2 more
      Apr 6, 2022

      BRAF V600E Mutation Present, BRAF V600K Mutation Present, Metastatic Malignant Solid Tumor Trial in Boston (Dabrafenib,

      Active, not recruiting
      • BRAF V600E Mutation Present
      • +9 more
      • Boston, Massachusetts
      • +1 more
      Jun 28, 2022

      Advanced Solid Tumors Trial in Worldwide (MEK162 + RAF265)

      Completed
      • Advanced Solid Tumors
      • MEK162 + RAF265
      • Tampa, Florida
      • +7 more
      Sep 28, 2020

      BRAF Inhibitor Encorafenib And Cetuximab Real Life Investigation

      Recruiting
      • Metastatic Colorectal Carcinoma
      • Aschaffenburg, Germany
      • +11 more
      Dec 13, 2020

      Melanoma Trial in Worldwide (encorafenib, binimetinib, pembrolizumab)

      Recruiting
      • Melanoma
      • Siena, Toscana, Italy
      • +11 more
      Jun 23, 2023